Cited by 662Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Kuchay, Mohammad Shafi, Krishan, Sonal, Mishra, Sunil Kumar, Farooqui, Khalid Jamal, Singh, Manish Kumar, Wasir, Jasjeet Singh, Bansal, Beena, Kaur, Parjeet, Jevalikar, Ganesh, Gill, Harmendeep Kaur, Choudhary, Narendra Singh, Mithal, Ambrish·2018·Diabetes Care

DOI 10.2337/dc18-0165

Open this paper in CoChat — free account

Abstract

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat are scarce. This study examined the effect of empagliflozin (an SGLT-2 inhibitor) on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) by using MRI-derived proton density fat fraction (MRI-PDFF). RESEARCH DESIGN AND METHODS Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks. Change in liver fat was measured by MRI-PDFF. Secondary outcome measures were change in alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transferase (GGT) levels. RESULTS When included in the standard treatment for type 2 diabetes, empagliflozin was significantly better at reducing liver fat (mean MRI-PDFF difference between the empagliflozin and control groups −4.0%; P < 0.0001). Compared with baseline, significant reduction was found in the end-of-treatment MRI-PDFF for the empagliflozin group (16.2% to 11.3%; P < 0.0001) and a nonsignificant change was found in the control group (16.4% to 15.5%; P = 0.057). The two groups showed a significant difference for change in serum ALT level (P = 0.005) and nonsignificant differences for AST (P = 0.212) and GGT (P = 0.057) levels. CONCLUSIONS When included in the standard treatment for type 2 diabetes, empagliflozin reduces liver fat and improves ALT levels in patients with type 2 diabetes and NAFLD.

Integrity signals

Registry

Crossref · 10.2337/dc18-0165

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
MOFRAD, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,199

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 657

Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus
Suzuki, Y., Kaneko, H., Okada, A., Ohno, R., Yokota, I., Fujiu, K., Jo, T., Takeda, N., Morita, H., Node, K., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02246-6 · Cited by 15
Association between plant and animal protein and biological aging: findings from the UK Biobank
Xu, X., Hu, J., Pang, X., Wang, X., Xu, H. Y., Yan, X., Zhang, J., Pan, S., Wei, W., & Li, Y. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03494-9 · Cited by 19
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 16
Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes
Kuchay, M. S., Choudhary, N. S., Mishra, S. K., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.015 · Cited by 17
Self-citation
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo, S., García–Tsao, G., & Taddei, T. H. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13136 · Cited by 15
Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 14
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 15
Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome
Goodheart, R. H., & Ayonrinde, O. T. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.009 · Cited by 18
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 13
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)
Rajeev, S. P., Roberts, C. A., Brown, E. E., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Perry, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15257 · Cited by 14
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus
Ng, H. Y., Zhang, L., Tan, J. T., Hui, R. W. H., Yuen, M., Seto, W., Leung, W. K., & Cheung, K. S. (2025) · Liver International · doi:10.1111/liv.70023 · Cited by 14
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Chábová, V. Č., & Zakiyanov, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052812 · Cited by 16
Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
Sinakos, E. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0704 · Cited by 16
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Suri, J. S., Borja, S., & Lim, J. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i35.5129 · Cited by 14
Recent updates on targeting the molecular mediators of NAFLD
Wang, J., Wang, L., Zhang, X., Zhang, P., Cai, J., She, Z., & Li, H. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02282-4 · Cited by 13
Macrovascular and microvascular type 2 diabetes complications are interrelated in a mouse model
Cifuentes‐Mendiola, S. E., Solís-Suárez, D. L., Martínez-Dávalos, A., & García‐Hernández, A. L. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108455 · Cited by 15
Nonalcoholic fatty liver disease
Makri, E. S., & Pοlyzos, S. A. (2022) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1030 · Cited by 16
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease
Aso, Y., Sagara, M., Niitani, T., Kato, K., Iijima, T., Tomaru, T., Jojima, T., & Usui, I. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001621 · Cited by 14
Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways
Noah, A. A., El-Mezayen, N. S., El-Ganainy, S. O., Darwish, I. E., & Afify, E. A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176066 · Cited by 13
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 13
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
Wakamatsu, S., Jojima, T., Hashiguchi, M., Kishi, H., Niitani, T., Sakurai, S., Iijima, T., Kogai, T., Tomaru, T., Usui, I., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108650 · Cited by 13
Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
Gao, X., Zhu, C., Zhu, W. M., & Wang, L. (2024) · Biomedical Reports · doi:10.3892/br.2024.1904 · Cited by 13
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
Yalçın, N., Aktaş, S., Uyar, S., & Koca, N. (2025) · Life · doi:10.3390/life15050722 · Cited by 15
NAFLD/NASH and Diabetes
Garg, K., BRACKETT, S. J., Hirsch, I. B., & Garg, S. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2513 · Cited by 13
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Bae, J., Huh, J. H., Lee, M., Lee, Y., & Lee, B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14259 · Cited by 13
Metabolomics study reveals the alteration of fatty acid oxidation in the hearts of diabetic mice by empagliflozin
Zhang, Y., Zhang, Z., Li, C., Tang, D., & Dai, Y. (2022) · Molecular Omics · doi:10.1039/d2mo00036a · Cited by 13
Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD
Iwaszko-Sochal, K., Kasztelan‐Szczerbińska, B., & Cichoż‐Lach, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176148 · Cited by 13
Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 13
Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes
Licata, A., Russo, G. T., Giandalia, A., Cammilleri, M., Asero, C., & Cacciola, I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030558 · Cited by 12
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 14
Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Ono, M., Nozaki, Y., et al. (2020) · doi:10.36502/2020/droa.6159 · Cited by 12
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Campos‐Toimil, M., García‐Caballero, T., Barral, L., Tarazón, E., Roselló‐Lletí, E., Portolés, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827033 · Cited by 12
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases
Miyazaki, R., & Miyagi, K. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02793-9 · Cited by 12
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
Dokmak, A., Almeqdadi, M., Trivedi, H. D., & Krishnan, S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i7.562 · Cited by 12
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 12
Self-citation
Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study
Bea, S., Jeong, H. E., Park, S., Yu, O. H. Y., Chang, Y., Cho, J., Sinn, D. H., Cho, Y. M., & Shin, J. (2022) · Gut · doi:10.1136/gutjnl-2022-327504 · Cited by 12
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
Tang, X., Zhang, H., Wang, X., & Yang, D. (2022) · African Health Sciences · doi:10.4314/ahs.v22i3.42 · Cited by 12
Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology
Yadav, J., Ahsan, F., Panda, P., Mahmood, T., Ansari, V. A., & Shamim, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271026231127051545 · Cited by 11
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
Shikamura, M., Takayama, A., Takeuchi, M., & Kawakami, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15632 · Cited by 11
Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
Shen, T., Aby, E. S., Vock, D. M., & Farley, J. F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15853 · Cited by 13
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Prasoppokakorn, T. (2025) · Livers · doi:10.3390/livers5010004 · Cited by 11
Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium‐glucose cotransporter 2 inhibitors: a retrospective study
Horii, T., Kozawa, J., Fujita, S., Hosokawa, Y., Kimura, T., Fujita, Y., Tokunaga, A., Fukui, K., & Shimomura, I. (2021) · Obesity Science & Practice · doi:10.1002/osp4.482 · Cited by 11
A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease
Zhang, Q., Zhang, L., Liu, K., Shang, H., Ruan, J., Yu, Z., Meng, S., Liang, F., Wang, T., Zhang, H., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1638740 · Cited by 11
Assessment of fatty liver and its correlation with glycemic control in patients with type 2 diabetes mellitus attending Dessie Comprehensive Specialized Hospital, Northeast Ethiopia
Abebe, G., Ayanaw, D., Mengstie, T. A., Dessie, G., & Malik, T. (2022) · SAGE Open Medicine · doi:10.1177/20503121221124762 · Cited by 11
Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
Kontana, A., & Τζιόμαλος, Κ. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i28.3664 · Cited by 11
Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?
Scheen, A. J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.39 · Cited by 11
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 11
Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases
Ge, M., Merscher, S., & Fornoni, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080820 · Cited by 11
A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat
Lee, M. H., Neeland, I. J., Rocha, N. D. A., Hughes, C., Malloy, C. R., & Jin, E. S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100161 · Cited by 11
New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 10
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement
Bhattacharya, I., Maity, D. K., Kumar, A., Sarkar, S., Bhattacharya, T., Sahu, A., Sreedhar, R., & Arumugam, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04257-x · Cited by 11
Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Takeshita, Y., Kanamori, T., Tanaka, T., Kaikoi, Y., Kita, Y., Takata, N., Iida, N., Arai, K., Yamashita, T., Harada, K., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00762-9 · Cited by 10
Empagliflozin is more Effective in Reducing Microalbuminuria and alt Levels Compared with Dapagliflozin: Real Life Experience
Günhan, H. G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.59 · Cited by 10
Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats
Hsu, S., Huang, H., Pun, C. K., Chang, C.-C., Chuang, C., Huang, Y., Hou, M., & Lee, F. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001289 · Cited by 10
The effects of the voglibose on non-alcoholic fatty liver disease in mice model
Bae, J., Lee, J. Y., Shin, E., Lee, M., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-15550-7 · Cited by 10
Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study
Althobaiti, F. M., Alsanosi, S., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Alghamdi, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164769 · Cited by 10
Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,
Zou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 11
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
Khaznadar, F., Petrovic, A., Khaznadar, O., Roguljić, H., Bojanić, K., Kuna, L., Siber, S., Smolić, R., Bilić-Čurčić, I., Wu, G. Y., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206561 · Cited by 12
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
Gorgojo-Martínez, J. J., Gargallo-Fernández, M., Sanz-Pastor, A. G., Antón-Bravo, T., Brito-Sanfiel, M., & Wong-Cruz, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072275 · Cited by 10
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 10
Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis
Amjad, W., Malik, A., Qureshi, W., Dennis, B. B., Mumtaz, M., Haider, R., Jamal, S. M., Jaura, F., & Ahmed, A. (2022) · Gastroenterology Review · doi:10.5114/pg.2021.112365 · Cited by 11
The Prevalence of Advanced Liver Fibrosis among Patients with Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia
Lee, X. H., Nur, L. M., Ang, C. S., Yeow, T. P., & Lim, S. L. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.08 · Cited by 9
Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
Choi, Y. J., Park, J.-H., Cho, H.-I., Shin, M., & Nah, E. (2025) · Metabolites · doi:10.3390/metabo15050299 · Cited by 10
Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
Das, C., Tripathy, D., Swain, S., Sudhakaran, N., Uthansingh, K., Mallick, P., & Pati, G. K. (2021) · Cureus · doi:10.7759/cureus.14974 · Cited by 10
Efficacy of Submicron Dispersible Free Phytosterols on Non-Alcoholic Fatty Liver Disease: A Pilot Study
Brañes, M. C., Gillet, R., & Valenzuela, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030979 · Cited by 9
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Colbert, G. B., Madariaga, H. M., Gaddy, A. R., Elrggal, M. E., & Lerma, E. V. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s398163 · Cited by 9
An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
Connelly, M. A., Rivera, J. V., Guyton, J. R., Siddiqui, M. S., & Sanyal, A. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15935 · Cited by 9
The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Aystematic Review and Network Meta-Analysis
Jalili, R., Somi, M. H., Hosseinifard, H., Salehnia, F., Ghojazadeh, M., Makhdami, N., & Shirmohammadi, M. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.065 · Cited by 8
New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
Stojsavljević, S., Duvnjak, M., Virović-Jukić, L., Hrabar, D., & Duvnjak, L. S. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00057 · Cited by 9
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
Finotti, M., Romano, M., Auricchio, P., Scopelliti, M., Brizzolari, M., Grossi, U., Piccino, M., Benvenuti, S., Morana, G., Cillo, U., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060499 · Cited by 9
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
Kim, D. Y., Chung, K. S., Park, J. Y., & Gee, H. Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114445 · Cited by 9
Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes
Sato, M., Tamura, Y., Kaga, H., Yamasaki, N., Kiya, M., Kadowaki, S., Sugimoto, D., Funayama, T., Someya, Y., Kakehi, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091154 · Cited by 8
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 10
Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study
Pereira, I. V. A., de Oliveira, A. B. S., Zitelli, P. M., Barbieri, L. A., Cardoso, A. C., Monteiro, M. J. D. S. D., de Oliveira, J. S., Stefano, J. T., Altikes, R. G., Reis, A. L. G., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100737 · Cited by 8
“Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis”
Abbas, M. S., Dandamudi, M., Rehman, T., Faizan, M. A., Zahra, I., Mojica, J. C., Ahmed, M. M. A., Bai, K., Shakeel, I., Shahzad, Z., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01797-0 · Cited by 8
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
Noh, S. W., Ryu, H. S., Kim, Y. H., & Oh, B. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2786 · Cited by 10
Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial
Zhang, L., Wang, T., Kong, Y., Sun, H., Zhang, Y., Wang, J., Wang, Z., Lu, S., Yu, P., & Zhou, S. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01236-1 · Cited by 8
Impact of tofogliflozin on hepatic outcomes: a systematic review
Pathak, M., Parveen, R., Khan, P. M., Saha, N., & Agarwal, N. B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03537-w · Cited by 8
Liver transplantation in the era of obesity: A metabolic public health crisis meets a surgical frontier
Rozani, S., Dalamaga, Μ., Weber, G., & Grützmann, R. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100410 · Cited by 7
Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial
Erfanifar, A., Nikpour, S., Davoudi, Z., Jolfaei, P., Toreyhi, H., & Nasab, S. N. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02098-6 · Cited by 10
De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
Han, M. A. T., Olivo, R., Choi, C. J., & Pyrsopoulos, N. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1991 · Cited by 7
The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
Goya, T., Imoto, K., Tashiro, S., Aoyagi, T., Takahashi, M., Kurokawa, M., Suzuki, H., Tanaka, M., Kato, M., Kohjima, M., et al. (2022) · Gastroenterology Insights · doi:10.3390/gastroent13010003 · Cited by 7
Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease
Ishikawa, T., Terai, N., Sato, R., Jimbo, R., Kobayashi, Y., Sato, T., Iwanaga, A., Sano, T., Yokoyama, J., & Honma, T. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3259-23 · Cited by 7
Empagliflozin add‐on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open‐label, single‐center, pilot clinical trial
Esmaeili, A., Azar, R. P., Hosseiniazar, M. M., & Gharabagh, L. H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.723 · Cited by 9
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 7
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 7
MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH
Wang, Y., Shen, Q.-L., Xin, Q., Sun, B., Zhang, S., Fang, Q., Shi, Y., Niu, W.-Y., Lin, J., & Li, C. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0022 · Cited by 7
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 9
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease
Chen, X., Xu, C., Hu, K., Yang, Y., Zhang, Y.-J., Shi, H.-Z., Gu, Q., He, S., Zhang, C., & Wang, D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2256224 · Cited by 6
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
Hupa‐Breier, K. L., Schenk, H. J., Campos-Murguía, A., Wellhöner, F., Heidrich, B., Dywicki, J., Hartleben, B., Böker, C., Mall, J. W., Terkamp, C., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102104 · Cited by 6
Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis
Yen, F., Hou, M., Wei, J. C., Huang, Y., Shih, Y., Pan, C., Wang, S.-T., Hwu, C., & Hsu, C. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70070 · Cited by 7
Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy
Lü, M., Zhao, Y., Liu, Z., Zhang, Y. H., & Liu, J. (2025) · Hepatology Research · doi:10.1111/hepr.70021 · Cited by 6
Obesity and Metabolic Syndrome in the 21st Century: A Narrative Review of Cardiometabolic Risk and Global Policy Response
Sanchez, D., León, E. M., Salgado, C. N. A., Martinez, Y. S., Figueroa, P. D., Escárcega, M. C., Cohen, A. H., Garcia, X. A. S., Guzman, J. A. R., & Haro, S. E. R. (2025) · Cureus · doi:10.7759/cureus.97204 · Cited by 8

Authors: Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., Choudhary, N. S., & Mithal, A.
Affiliations: Medanta The Medicity (IN)
Corresponding author: Kuchay, Mohammad Shafi
ORCID: Kuchay, Mohammad Shafi
Mishra, Sunil Kumar
Singh, Manish Kumar
Bansal, Beena
Kaur, Parjeet
Jevalikar, Ganesh
Choudhary, Narendra Singh
Mithal, Ambrish
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2018-06-12
Volume: 41
Issue: 8
Pages: 1801-1808
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc18-0165
OpenAlex: W2808615577
Cited by: 662
References: 40
Citations by year: 2026: 81 · 2025: 98 · 2024: 73 · 2023: 86 · 2022: 85 · 2021: 78 · 2020: 88 · 2019: 52 · 2018: 18
FWCI: 46.08
Type: journal article
Language: en
Open access: closed
Licence: www.diabetesjournals.org/content/license (vor, 38 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Endocrine and Diabetes Foundation, India
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: empagliflozin, SGLT2 inhibitors, liver fat, non-alcoholic fatty liver disease, type 2 diabetes, proton density fat fraction, alanine aminotransferase, liver enzymes
MeSH terms: Adipose Tissue, Adult, Alanine Transaminase, Aspartate Aminotransferases, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Treatment Outcome, Adiposity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks